EP2858671
Mótefnissamsetning
Status:
EP einkaleyfi í gildi á ÍslandiEP appl. date:
11.6.2013EP published:
24.7.2019EP application number:
13744818.9
EP translation filed:
9.10.2019Grant published:
15.11.2019EPO information:
European Patent Register
Max expiry date:
10.6.2033Expiry date:
10.6.2026Next due date:
30.6.2026
Title:
ANTIBODY FORMULATION
Timeline
Today
11.6.2013EP application
24.7.2019EP Publication
9.10.2019Translation submitted
15.11.2019Registration published
10.6.2026Expires
Owner
Name:
Novartis AGAddress:
Lichtstrasse 35, 4056, Basel, CH
Inventor
Name:
COSENZA, MartaAddress:
Basel, CH
Name:
STARK, ChristophAddress:
Basel, CH
Agent
Name:
Árnason Faktor ehf.Address:
Guðríðarstíg 2-4, 113, Reykjavík,
Priority
Number:
201261658472 PDate:
12.6.2012Country:
US
Classification
Categories:
A61K 39/395, A61K 9/00, A61K 47/18, A61K 47/26, C07K 16/28
Annual fees
Number
Paid
Expires
Payer
Number: 8
Paid: 26.5.2020
Expires: 10.6.2021
Payer: Árnason Faktor ehf.
Number: 9
Paid: 25.5.2021
Expires: 10.6.2022
Payer: Árnason Faktor ehf.
Number: 10
Paid: 24.5.2022
Expires: 10.6.2023
Payer: Árnason Faktor ehf.
Number: 11
Paid: 24.5.2023
Expires: 10.6.2024
Payer: Árnason Faktor ehf.
Number: 12
Paid: 23.5.2024
Expires: 10.6.2025
Payer: Árnason Faktor ehf.
Number: 13
Paid: 10.6.2025
Expires: 10.6.2026
Payer: Árnason Faktor ehf.